Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of Live Attenuated Varicella Vaccine Co-administered with MMR Vaccine or DTaP Vaccine
Sponsor: Sinovac (Dalian) Vaccine Technology Co., Ltd.
Summary
This is a phase Ⅳ clinical trial of live attenuated varicella vaccine manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.The primary objective of this study is to evaluate the immunogenicity of live attenuated varicella vaccine co-administered with MMR vaccine or DTaP vaccine. The secondary objective is to evaluate the safety of the vaccines when administered simultaneously.
Official title: Immunogenicity and Safety of Live Attenuated Varicella Vaccine Co-administered with MMR Vaccine or DTaP Vaccine in Healthy Children Aged 18~24 Months: an Open-label, Randomized, Phase Ⅳ Study Clinical Trial
Key Details
Gender
All
Age Range
18 Months - 24 Months
Study Type
INTERVENTIONAL
Enrollment
720
Start Date
2025-05
Completion Date
2025-12
Last Updated
2025-03-24
Healthy Volunteers
Yes
Interventions
Vaicella Vaccine+DTaP on Day 0, MMR on Day 30
Varicella vaccine: lyophilized powder, subcutaneous injection DTaP: intramuscular injection MMR: lyophilized powder, subcutaneous injection
Varicella vaccine+MMR on Day 0,DTaP on Day 30
Varicella vaccine: lyophilized powder, subcutaneous injection MMR: lyophilized powder, subcutaneous injection DTaP: intramuscular injection
Varicella Vaccine
lyophilized powder, subcutaneous injection
Locations (1)
Chongqing Center for Disease Control and Prevention
Chongqing, China